Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study

C P Williams, D F Child, P R Hudson, G K Davies, M G Davies, R John, P S Anandaram, A R De Bolla

Abstract

Aims—To investigate whether increasing the daily baseline of gut calcium can cause a gradual downregulation of the active intestinal transport of calcium via reduced parathyroid hormone (PTH) mediated activation of vitamin D, and to discuss why such a mechanism might prevent calcium oxalate rich stones. To demonstrate the importance of seasonal effects upon the evaluation of such data.

Methods—Within an intensive 24 hour urine collection regimen, daily calcium supplementation (500 mg) was given to five stone formers for a 10 week period during a six month crossover study. In a further population of patients on follow up for previous renal stone disease, observations were made on 1066 24 hour urine samples collected over five years in respect of seasonal effects relevant to the interpretation of the study.

Results—In the group of patients on calcium supplements the following results were found. During calcium supplementation, the proportion of urine calcium to oxalate was higher (increased calcium to oxalate molar ratio), the 24 hour urine product of calcium and oxalate did not rise, and urine oxalate was lower during the first six weeks of supplementation. Twenty four hour urine calcium was 10.2% higher than baseline in the final four weeks of the 10 weeks of supplementation. Twenty four hour urine phosphate was 11.4% lower during the first six weeks of supplementation, but then rose while the patients were still on supplementation; renal tubular reabsorption of phosphate (TmP/GFR) mirrored the urine phosphate changes inversely. PTH was higher after stopping supplementation, but 1,25-(OH)2-cholecalciferol changes were not seen.

Conclusions—Regular calcium supplementation does not raise the product of calcium and oxalate in urine and the proportion of oxalate to calcium is reduced.

The underlying mechanisms of the changes seen in phosphate, calcium, and PTH and the observations on 1,25-(OH)2-cholecalciferol are not clear. Observed changes in phosphate could possibly be part of a calcium regulating feedback loop operating over a period of weeks. In evaluating these mechanisms background seasonal effects are important. It is possible that “programming” of the gut mucosa in terms of calcium transport is a major determinant of the relation between calcium and oxalate concentrations in urine and their relative abundance. Increased oral calcium, in association with a reduction of the relative proportion absorbed, may be pertinent to the prevention of calcium oxalate rich stones.

Keywords: renal stones; calcium oxalate product; dietary calcium; renal tubular reabsorption of phosphate

Humans evolved in a calcium rich environment before the advent of farming 10 000 years ago. Few renal stones are associated with early skeletal remains,1 yet the consumption of calcium by early humans was three to five times that of people in modern industrialised countries, where up to 10% of men and 3% of women have renal stones at some time in their life.2–6 Why should this be? A major prospective study by Curhan et al in North America showed in a cohort of 45 000 men that the risk of symptomatic stone disease was less for those with higher dietary calcium.7 Previous dietary work concentrated upon avoiding the saturation of urine by using low calcium and low oxalate diets,8 but dietary evidence increasingly shows that a higher intake of calcium is associated with lower urinary oxalate and decreased renal stone formation.9–16 Our traditional focus upon reducing calcium intake in renal stone formers now seems to be inappropriate. In a recent study17 of 34 stone formers prescribed a low calcium diet for 30 days, there was a pronounced increase in urine oxalate, with a deleterious effect on relative supersaturation of calcium oxalate. If the extremely complex process of calcium regulation evolved to cope with a different calcium supply to the present one, are we simply at the design limits of the regulatory process or overriding components of it by vitamin D supplementation? Fraser’s18 notes that none of the terrestrial land based vertebrates maintain their vitamin D status from a nutritional source, but as little as 25 µg (1000 IU) of vitamin D has been shown to be
causally associated with stones. We have personally noted with concern the number of our patients who have taken vitamin D before their stone episode, and a correlation between 1,25-(OH)₂-cholecalciferol and urine calcium and urine oxalate has been demonstrated in stone formers.

About 80% of renal stones are predominantly composed of calcium oxalate and up to half the patients have hypercalcuria. In this group, preventative treatment has traditionally reduced the oral intake of both calcium and oxalate. The risk, however, of controlling calcium at the expense of oxalate has been emphasised because calcium oxalate saturation increases rapidly with a small increase in urine oxalate. Small increases in urine oxalates are much more important for augmenting the risk of stones than are large increases in urine calcium. A detailed review of this area can be found in Robertson and Peacock (1980).

A major impediment to this study has been the recruitment of individuals willing to take calcium supplements against a traditional practice resolutely to the contrary. Our objective was to find out whether increasing the daily baseline of calcium reaching the gut might gradually cause a downregulation of the processes governing active intestinal transport of calcium by a reduction of parathyroid hormone (PTH) mediated conversion of 25-(OH)-cholecalciferol to 1,25-(OH)₂-cholecalciferol. In a previous study, our key observations were the following: (1) during oral calcium loading, renal stone formers as a group exhibit a greater degree of phosphaturia for any given serum calcium concentration than control subjects; and (2) mean 1,25-(OH)₂-cholecalciferol was higher in the stone formers. Of particular relevance, Alvarez-Arroyo and colleagues suggested that serum phosphate values are lower in patients with absorptive hypercalciuria and raised 1,25-(OH)₂-cholecalciferol. As essential background to these observations, there is strong evidence that phosphate has a major role in the regulation of the concentration of 1,25-(OH)₂-cholecalciferol. In essence, decreased availability of phosphate increases 1,25-(OH)₂-cholecalciferol and hypophosphataemia is associated with high 1,25-(OH)₂-cholecalciferol values.

The renal tubular reabsorption of phosphate (TmP/GFR), described as the “renal threshold phosphate concentration”, has been used in this study as a presumptive index of the physiological effect of PTH on phosphate excretion. TmP/GFR is independent of GFR and the net inflow of phosphate into the intracellular space from bone, gut, and soft tissue. An extensive review by Crook and Swaminatham of disorders of phosphate transport protein recently recognised in bony
fish, but also encoded by the human genome. It is known experimentally to stimulate mucosal phosphate absorption in mammals and is a further important unknown factor.

Our present study was undertaken to determine what effects calcium supplements might have upon calcium and oxalate in urine. We measured the molar ratio of calcium to oxalate and the calcium and oxalate product. This product is a very “crude” index for clinical purposes because it does not test the supersaturation of urine with respect to calcium oxalate. It does not allow for complexing of oxalate by calcium; this latter phenomenon is the factor that has the most effect on the free ion concentration of oxalate and is the main determinant of the supersaturation of urine with respect to calcium oxalate under normal situations. However, the calcium and oxalate product does afford an insight into the overall regulation of calcium and oxalate metabolism, and the molar ratio indicates the relative proportions of calcium and oxalate. We explore the thesis that stone formers might “over react” to the relative calcium starvation of the modern diet with phosphaturia, and investigate the possibility of reducing their phosphaturia and downregulating cholecalciferol activation by means of sustained calcium supplementation. Such a mechanism could lead to less calcium being absorbed, which would raise the proportion of oxalate “trapped” in the gut. The season of the year is well known to affect calcium and possibly oxalate excretion, and for this reason we have abstracted data over five years to compensate for natural background effects relating to the period of the patient study and to indicate the overall magnitude of such changes. Extensive work undertaken during the 1970s by Rose32 33 in London and the mineral metabolism unit at Leeds,34 35 and later by others, demonstrates raised calcium in the summer and usually raised oxalate. Although urine phosphate appeared to be higher in the summer, there were no significant seasonal differences in 246 male stone formers in observations by Robertson,36 and there were no differences in a study of UK doctors,36 or in 147 institutionalised elderly patients.37 Urine phosphate was lower in the March to August period of the year in 118 male stone formers on a “free diet” reported by Juuti et al.38

### Methods

**SELECTION OF PATIENTS**

Eight male patients with confirmed renal stones were recruited to the study and five completed it. Their ages ranged from 44 to 63 years. All exhibited hypercalciuria (calcium > 7.5 mmol/24 hours) and hyperoxaluria (oxalate > 400 µmol/24 hours) at some time during their management. Urinary tract anatomical defects, hyperuricosuria, renal tubular acidosis, and cystinuria were excluded. Patients did not receive medication in the three months preceding our study.

In a further study, the results of 24 hour urine collections of all patients on regular follow up for renal stone disease over the previous five years were collected on to a database. All patients with less than two samples collected within this period were excluded. Because patients had been instructed to maintain a 24 hour urinary volume of around 2.5 litres, those samples with volumes less than 2 litres and greater than 3 litres were rejected, to exclude urine samples that might have been overcollected and undercollected. In addition, results from a patient known to have malabsorption were excluded. The resulting database comprised 246 patients and a total of 1066 individual urine collections. For the purposes of statistical analysis, the samples were coded as to whether they were collected during the “light” months of the year (May to October) or the “dark” months, and they were also coded...
“1” to “5” if they were collected at the same time of the year as the periods of the trial (June to July, July to mid August, mid August to mid September, mid September to November, and November to December, respectively). The purpose of collecting these data was to test for an overall correlation between calcium and oxalate and to demonstrate background changes in calcium, oxalate, and phosphate that might have a bearing on the interpretation of the data from our patient study group.

STUDY DESIGN

Ethics committee approval was obtained for our study. Figure 1 depicts the five periods of our study. Periods 1, 3, and 5 represent steady states subject to the effects of background factors. During periods 2 and 3, 500 mg of calcium was added in the morning to the patients’ normal diet as one Calci chew tablet (Shire Pharmaceuticals Ltd, Hampshire, UK). During periods 2 and 4, changes occurred in the equilibrium corresponding to starting or stopping calcium supplements, respectively. Six weeks (the length of these periods) was “allowed” for this prospectively, on the basis of clinical experience in the use of cholecalciferol and delay in reaching calcium equilibrium from dose adjustment. We assumed that, in the achievement of a steady state the processes of response to a change in calcium intake will feedback in some manner on cholecalciferol.

Eight 24 hour urine samples were collected in each of periods 1, 3, and 5, together with six in each of periods 2 and 4. Four samples of serum were collected in each of periods 1, 3, and 5, and three samples in each of periods 2 and 4. Abdominal x ray was performed within three months before and after completion of our study. Patients maintained a urine output of at least 2.5 litres/24 hours; they were equipped with a measuring cylinder and urine volume chart as part of their standard management. They were asked not to make any changes to their overall dietary practices. None were or had been on calcium restricted diets.

LABORATORY ANALYSES

Calcium, albumin, phosphate, and creatinine were measured by standard laboratory procedures (Synchron CX7; Beckman Instruments (UK) Ltd, High Wycombe, Buckinghamshire, UK). Serum calcium was corrected for the serum albumin concentration using a relation derived from a local population study: corrected calcium = serum total calcium × (albumin × 0.017) + 0.692. TmP/GFR was calculated from serum phosphate and creatinine results and from a contemporaneous 24 hour urine. Urine oxalate was measured by a commercial oxalate oxidase method (catalogue number 591-C; Sigma-Aldrich Co Ltd, Poole, Dorset, UK). The urine calcium times oxalate product was calculated by multiplying together three months before and after completion of our study. Patients maintained a urine output of at least 2.5 litres/24 hours; they were equipped with a measuring cylinder and urine volume chart as part of their standard management. They were asked not to make any changes to their overall dietary practices. None were or had been on calcium restricted diets.

was 0.155 (95% confidence interval, 0.045 to 0.266; p = 0.006). Previous renal stone disease. The regression parameter associated with the regression line was 0.155 (95% confidence interval, 0.045 to 0.266; p = 0.006).
Table 1 Phosphate, calcium, and oxalate excretion and calcium × oxalate product in 1066 individual 24 hour urine samples collected by 246 patients over a five year period

<table>
<thead>
<tr>
<th>Period</th>
<th>Calcium × oxalate (µmol/24 h)</th>
<th>Phosphate excretion (µmol/24 h)</th>
<th>Oxalate excretion (µmol/24 h)</th>
<th>Calcium x oxalate product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dark</td>
<td>3372 (2950 to 3819)</td>
<td>31.7 (31.3 to 32.2)</td>
<td>372 (363 to 382)</td>
<td></td>
</tr>
<tr>
<td>Light</td>
<td>3372 (2950 to 3819)</td>
<td>31.7 (31.3 to 32.2)</td>
<td>372 (363 to 382)</td>
<td></td>
</tr>
</tbody>
</table>

Samples were coded “dark” and “light” according to whether they were collected November to April or May to October, respectively.

p Values were assessed using the Bonferroni post to hoc test after two way ANOVA (results classified by “period number” and “time of year”).

Mean results are given with 95% confidence intervals.

p Values refer to the effect of the time of year in a two way ANOVA (results classified by “patient number” and “time of year”).

Results

Mean calcium excretion was higher in period 3 on supplements (10.41 mmol/24 hours; 95% CI, 9.20 to 11.79) than either baseline period 1 (9.45 mmol/24 hours; 95% CI, 8.37 to 10.68) or period 5 (8.74 mmol/24 hours; 95% CI, 7.79 to 9.81) when the patients were off calcium supplements (fig 2A). Urine oxalate excretion fell to 361 µmol/24 hours (95% CI, 331 to 396) in period 2 (on calcium supplements), compared with the baseline period 1 (406 µmol/24 hours; 95% CI, 375 to 440; fig 2B). The urine calcium times oxalate product fell to 3465 (95% CI, 2796 to 4294) in period 2 (on calcium supplements) from a baseline figure of 3826 (95% CI, 3208 to 4561) in period 1 (fig 2C), but this did not reach significance. In contrast, the urine-calcium to oxalate ratio rose from a baseline value of 24.8 mmol/mmol (95% CI, 21.6 to 28.0) to a value of 28.1 (95% CI, 24.1 to 32.2; p = 0.03) in period 2 and 27.8 (95% CI, 21.8 to 33.8; p = 0.049) in period 3.

Mean urine phosphate fell from a baseline value of 36.9 mmol/24 hours (95% CI, 33.8 to 39.8) to 32.7 (95% CI, 29.5 to 36.3) in period 2 (on calcium supplements; fig 3A). This change was mirrored by an apparent increase in TmP/GFR from 0.65 mmol/litre (95% CI, 0.51 to 0.78) in the baseline period to 0.72 (95% CI, 0.59 to 0.85) in period 2 (fig 3B).

To increase the statistical power of between period tests of serum components, the data for periods 2 and 3 (on calcium supplements) and periods 4 and 5 (off calcium supplements) were pooled. Mean serum calcium rose to 2.42 mmol/litre (95% CI, 2.39 to 2.45) in

Table 2 Phosphate, calcium, and oxalate excretion in 1066 individual 24 hour urine samples collected by 246 patients over a five year period

<table>
<thead>
<tr>
<th>Period</th>
<th>Phosphate excretion (µmol/24 h)</th>
<th>Calcium excretion (µmol/24 h)</th>
<th>Oxalate excretion (µmol/24 h)</th>
<th>Calcium x oxalate product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Period 1</td>
<td>36.9 (32.3 to 36.7)</td>
<td>7.0 (6.3 to 7.6)</td>
<td>39.8 (37.3 to 42.7)</td>
<td>2.42 (2.39 to 2.45)</td>
</tr>
<tr>
<td>Period 2</td>
<td>35.5 (31.9 to 37.7)</td>
<td>6.7 (6.3 to 7.6)</td>
<td>39.8 (37.3 to 42.7)</td>
<td>2.42 (2.39 to 2.45)</td>
</tr>
<tr>
<td>Period 3</td>
<td>34.7 (31.9 to 37.7)</td>
<td>6.5 (6.3 to 7.6)</td>
<td>39.8 (37.3 to 42.7)</td>
<td>2.42 (2.39 to 2.45)</td>
</tr>
<tr>
<td>Period 4</td>
<td>34.7 (31.9 to 37.7)</td>
<td>6.5 (6.3 to 7.6)</td>
<td>39.8 (37.3 to 42.7)</td>
<td>2.42 (2.39 to 2.45)</td>
</tr>
<tr>
<td>Period 5</td>
<td>34.7 (31.9 to 37.7)</td>
<td>6.5 (6.3 to 7.6)</td>
<td>39.8 (37.3 to 42.7)</td>
<td>2.42 (2.39 to 2.45)</td>
</tr>
</tbody>
</table>

Samples were coded “1” to “5” if they were collected at the same time of the year as the periods of the trial (June to July, July to mid August, mid August to mid September, mid September to November, and November to December, respectively).

Mean results are presented with 95% confidence intervals.

p Values were assessed using the Bonferroni post to hoc test after two way ANOVA (results classified by “period number” and “patient number”).
periods 4 and 5, compared with 2.35 (95% CI, 2.31 to 2.39) in the baseline period 1 (fig 4A). There was no significant change in serum 1,25-(OH)₂-cholecalciferol throughout the study (fig 4B). Serum PTH rose to a mean value of 2.74 pmol/litre (95% CI, 2.43 to 3.04) in periods 4 and 5, compared with 2.08 pmol/litre (95% CI, 1.73 to 2.44) in periods 2 and 3 (fig 4C).

In the 1066 individual 24 hour urines collected by 246 patients on follow up for previous renal stone disease over a five year period, the effect of categorical (patient number) and continuous (log calcium excretion) variables upon “log oxalate excretion” was tested using an ANOVA model. The results showed an increase in urine oxalate excretion with increasing calcium excretion (fig 5). The regression parameter associated with “log calcium excretion” was 0.155 (95% CI, 0.045 to 0.266; \( p = 0.006 \)).

In this population, there was a rise in urine phosphate excretion from 32.5 mmol/24 hours in the dark months of the year to 33.3 mmol/24 hours in the light months (table 1). Similarly, there was a rise in calcium excretion from 6.37 mmol/24 hours to 6.72 mmol/24 hours and a rise in the calcium times oxalate product from 2372 to 2493. There was no change in oxalate excretion. From the data presented in table 2, calcium and phosphate excretion would “normally” be lower in periods 4 or 5 of the trial (mid September to December), compared with results from earlier in the summer (June to August). Oxalate did not show any change within this time interval. The overall trends are depicted in the broken lines in figs 2A, 3A, and 2C, respectively.

Discussion

Two key observations have been made in this pilot group of stone formers, namely: (1) on 500 mg oral calcium supplements, the molar ratio of calcium to oxalate increased in urine without raising the calcium times oxalate product and (2) the urine phosphate fell 10% during the first six weeks of calcium supplementation, rising thereafter while remaining on supplements. Also of key relevance, in a further 246 stone formers, 24 hour urine calcium and oxalate were positively correlated. The observation that these two variables are not inversely related, as in feeding experiments (described below), is important to the discussion as are background seasonal changes in calcium and, in particular, phosphate.

The recruitment of individuals willing to keep up the programme of 24 hour urine collections was difficult. Within our clinic, intra-individual variation in 24 hour urine calcium and oxalate occurs by up to a factor of four over several months, and volunteers are not willing to undertake the number of 24 hour urine collections necessary to compensate for natural variation. Under the study conditions, urine oxalate excretion varied by a factor of up to eight in a single patient within a single period. This limits the statistical strength of the data.

Calcium and oxalate exist in the gut as free calcium and oxalate ions in equilibrium with the sparingly soluble calcium oxalate complex formed by the chelation of calcium by oxalate. In short term feeding experiments and dietary observations a low calcium diet raises urine oxalate and vice versa. However, we found that calcium and oxalate are positively correlated in urine. How can this be reconciled with the gut chelation process? Regulation of calcium absorption by the gut mucosa would explain this paradox—a decreased proportion of calcium absorbed in the gut would reduce urine calcium excretion and retain calcium in the gut to be chelated by oxalate. Changes in the true proportion of calcium being absorbed would therefore affect both urine calcium and oxalate in the same direction. Active gut mucosal transport of calcium is facilitated by a family of cholecalciferol dependent “calcium binding proteins” (CaBP-Ds). The fall in urine phosphate during the first six weeks of supplementary calcium (fig 3A) might theoretically mark reduced activation of cholecalciferol (that is, reduced conversion of 25-(OH)₂-cholecalciferol to 1,25-(OH)₂-cholecalciferol) via reduced PTH as part of a long feedback loop relating to calcium homeostasis. Although half lives of both substances have been ascribed to CaBP-Ds, it seems more likely that their intestinal life is measured in hours, although they could be subject to a long feedback mechanism. Establishment of precursors for phosphate excretion in period 3, apparent both in 24 hour urine phosphate and an increase in renal phosphate clearance (as decreased TmP/GFR), may signal resumed production of 1,25-(OH)₂-cholecalciferol by hydroxylation of 25-(OH)₂-cholecalciferol.

Clearly, the flaw with this speculation is the absence of evident change in 1,25-(OH)₂-cholecalciferol even though the equilibrium time in its production is said to be 15 hours. A study in normal subjects did indeed demonstrate a decline in 1,25-(OH)₂-cholecalciferol (with no PTH change) over a six to seven week period, but the calcium supplement was 2 g. Deductions from our data are limited by possible differences in the cholecalciferol receptor status of individuals. Increases in the number of cholecalciferol receptors on activated lymphocytes have been found in some patients with absorptive hypercalciuria. A major variable affecting these data is that periods 2 and 3 covered June to mid August, the theoretical advantage being that any demonstrated 1,25-(OH)₂-cholecalciferol reduction would be set against the period of maximum sunlight and therefore not attributable to seasonal variation as noted in other studies. The practical importance of seasonal variation in relation to this type of work is illustrated in table 1, where mean urine calcium is 5.5% higher in light compared with dark months. The overall trend is illustrated in fig 2A. In period 3 (on calcium supplements), mean urine calcium rose by 10.2% compared with the period 1 baseline. Therefore, net absorption of the 500 mg (12.5 mmol) calcium supplement was 7.8%. To what extent this might encompass a...
seasonal effect is difficult to say, but net absorption might be significantly less than 7.8% of the supplementary calcium. A 7.8% (or below) net absorption of supplementary calcium is proportionally less than the “normal” one quarter net absorption. Equilibrium may not have been established (fig 2A) and longer term studies would be of interest. These discussions presuppose that oxalate is not actively transported. There is a recent suggestion that oxalate or sulphate might be coupled indirectly with the reabsorption of chloride,\(^4\) and work in the past has suggested a possible indirect role of bile acids,\(^3\) but oxalate conventionally is thought to be absorbed passively.\(^4\)\(^5\)

In a previous study, we have shown that renal stone formers intrinsically have a greater degree of phosphaturia.\(^2\) This study was designed to determine whether daily calcium supplementation could reduce the phosphaturia, thereby reducing the PTH element of the stimulus to the activation of cholecalciferol, and hence the gut calcium absorbed. The reduction in phosphate excretion in period 2 of calcium supplementation is compatible with this concept, but an alternative explanation would be that calcium is simply binding phosphate in the gut. “Calcichew” contains calcium as CaCO\(_3\), and its alkaline nature would therefore favour precipitation of phosphate as calcium phosphate in the gut. The subsequent increase in urine phosphate while on the same calcium supplementation is contrary to this. There are two further considerations relating to possible phosphate precipitation. First, it could be argued that the raised urine calcium of period 3 implies that there might then be less calcium in the gut to be precipitated with phosphate, hence the rise in urine phosphate. This would require that calcium absorption improved after six weeks of calcium supplements, at a time when there is no evidence of a background (table 2; fig 2A) increase in urine calcium. Second, it could be argued that the absence of a rise in urine phosphate on stopping calcium supplements did not exclude a phosphate precipitation mechanism explaining the observations because phosphate fell in the “background” group observed over five years (that is, there was therefore relative phosphaturia in the study patients; table 2; fig 3A). The higher PTH concentrations in the study patients in periods 2 and 3 combined also favour this point. In respect of the rise in 24 hour urine calcium that occurred after six weeks of calcium supplementation, our favoured explanation is that if PTH is initially reduced by calcium supplementation, mobilisation of calcium from bone will be reduced, but the effect offset by a rise in the renal clearance of calcium from the direct effect of PTH on renal tubules and the calcium supplement itself. However, TmP/GFR fell in period 3, which could be interpreted to reflect higher PTH activity. Therefore, increased PTH might be responsible for an increase in urine calcium in period 3 (fig 2A) because, although the direct renal tubular effect will be to reduce calcium excretion,\(^2\) bone mobilisation will have been increased/resumed to the former value. This, together with the calcium supplement, would raise urinary calcium.

Within its limits, we have used TmP/GFR\(^2\) as the physiological index of PTH, and the absence of demonstrable changes in PTH during these periods should not be taken as negative evidence, because differences can be demonstrated between groups defined in terms of TmP/GFR that are not manifest in PTH.\(^2\) Nevertheless, there are important problems of diurnal variation with TmP/GFR,\(^5\) with values rising from about 11:00 to 03:00 hours, but blood was taken from patients in the mornings in a non-fasting state. PTH also has the disadvantage of episodic release and a range of molecular fragments, the full physiological nature of which remain undefined. Mean serum calcium appeared to rise (not significantly) during periods 2 and 3 (fig 4A) and was even 0.07 mmol/litre higher in combined periods 4 and 5 (off calcium supplements) than at the original baseline (period 1). The serum calcium rise off supplements was unexpected—we have not found other reports of such an effect—but in correspondence with our external quality assurance organiser it was agreed that it could not be attributed to assay drift and does broadly correspond with the PTH observations in the same periods (fig 4C). Thus, PTH is higher in periods 3 and 4 combined (off calcium supplements) than periods 2 and 3 combined (on calcium). This is not reflected in increased phosphaturia or decreased TmP/GFR, but a comparison of fig 3A and table 2 suggests that phosphaturia is “hidden” by a seasonal decline in urine phosphate and that a relative phosphaturia does indeed exist. Basal PTH values have been shown to be seasonally dependent, with higher values seen after winter,\(^6\) but the observed variables and potential variables are such that we have not attempted to speculate further, and we present the information within its many limitations as found. Oral calcium has also been given to children in what the authors described as the first study of short term and “long term” (one week) calcium loading in idiopathic hypercalciuria.\(^7\) No change was evident in 1,25-(OH)\(_2\)-cholecalciferol and they hypothesised that “autonomously raised” 1,25-(OH)\(_2\)-cholecalciferol production is a possible mechanism for idiopathic hypercalciuria. We note (fig 3A) the rise in urine phosphate, after an initial decline, during the period of supplementation and suggest that it might be part of a long feedback loop regulating calcium metabolism, which might even relate to the metabolism of cholecalciferol. A fundamental basic problem in attempting to explain the data in this type of study is the number of variables and we do not know whether we are in fact witnessing the putative phosphaturic hormone\(^8\)\(^9\) at work.

We think that these findings are of relevance to clinical practice. The correlation between urine calcium and oxalate suggests that programming of gut mucosal transport of calcium is a key to the relation between calcium and oxalate in urine. The reduction of mucosal calcium transport has two benefits: not only is
Oral calcium supplements and renal stone disease

We recommend that vitamin D is integral to the regulation of calcium supplementation. More importantly, more calcium will be available in the gut to chelate oxalate, with possible benefits upon urine supersaturation. With an "all or nothing" element to the formation of crystals, even a modest reduction in urine saturation below a critical threshold may be crucial. We assume that it is the height of the peaks as opposed to the width that is critical in concentration terms. In essence, patients might have the advantage of absorptions more slowly even if they absorb no less. Integrated values over 24 hours matter less than their peak concentrations at any point in time. Superimposed upon these considerations are circadian rhythms of calcium, oxalate, and phosphate, which have been shown to affect saturation and lithogenic risk.12-15 We recommend that these factors should be explored in terms of the effects of calcium supplementation.

As a concluding observation, we note that vitamin D is integral to the regulation of calcium metabolism and ask whether fortification of the national diet with vitamin D and public interest in vitamin D supplements does not have a more important underlying role in the generation of some renal stones than the literature would suggest. We recommend that this suggestion should be considered further.

We would like to thank Mrs P Walsh for her very expert administrative help with our study.


Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study

C P Williams, D F Child, P R Hudson, G K Davies, M G Davies, R John, P S Anandaram and A R De Bolla

*J Clin Pathol* 2001 54: 54-62
doi: 10.1136/jcp.54.1.54

Updated information and services can be found at:
http://jcp.bmj.com/content/54/1/54

These include:

**References**

This article cites 47 articles, 8 of which you can access for free at:
http://jcp.bmj.com/content/54/1/54#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/